Allarity Therapeutics (ALLR) Income from Continuing Operations (2020 - 2026)
Allarity Therapeutics' (ALLR) quarterly Income from Continuing Operations came in at 2754000.0 in Q1 2026, down 0.81% YoY from 2776357.2 in Q1 2025, and up 18.35% on a QoQ basis from 3373000.0 in Q4 2025.
Allarity Therapeutics (ALLR) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Allarity Therapeutics (ALLR) has 7 years of Income from Continuing Operations data on file, last reported at 2754000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 0.81% year-over-year to 2754000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 11253000.0 (down 60.12% YoY) and the FY2025 annual result came in at 11231000.0, down 37.99% from the prior year.
- Income from Continuing Operations advanced to 2754000.0 in Q1 2026, from 3373000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 8923000.0 in Q4 2024 to a low of 11590000.0 in Q3 2024.
- A 5-year average of 2795176.47 and a median of 2838000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations tumbled 272.83% — and 2024, when it jumped 958.48%.
- Tracing ALLR's Income from Continuing Operations over 5 years: stood at 2838000.0 in 2022, then jumped by 129.7% to 843000.0 in 2023, then jumped by 958.48% to 8923000.0 in 2024, then tumbled by 137.8% to 3373000.0 in 2025, then climbed by 18.35% to 2754000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 2754000.0 (Q1 2026), 3373000.0 (Q4 2025), and 2806000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Allarity Therapeutics | 22.75 Mn | 22.75 Mn | - | -3.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.75 Mn |
| Dec 31, 2025 | -3.37 Mn |
| Sep 30, 2025 | -2.81 Mn |
| Jun 30, 2025 | -2.32 Mn |
| Mar 31, 2025 | -2.73 Mn |
| Dec 31, 2024 | 8.92 Mn |
| Sep 30, 2024 | -11.59 Mn |
| Jun 30, 2024 | -1.63 Mn |
| Mar 31, 2024 | -3.84 Mn |
| Dec 31, 2023 | 843,000.00 |
| Sep 30, 2023 | -4.45 Mn |
| Jun 30, 2023 | -2.38 Mn |
| Mar 31, 2023 | -3.35 Mn |
| Dec 31, 2022 | -2.84 Mn |
| Sep 30, 2022 | -5.04 Mn |
| Jun 30, 2022 | -5.10 Mn |
| Mar 31, 2022 | -3.08 Mn |
| Dec 31, 2021 | -16.82 Mn |
| Sep 30, 2021 | -1.35 Mn |
| Jun 30, 2021 | -5.40 Mn |